Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | MARK3 | P27448 | 1/20 | 0.47 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.47 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10819499 | 1.00 | L3MBTL1 (0.57) | L3MBTL1MEN1KMT2APIM1MARK3 | |
| SCHEMBL1196430 | 0.83 | L3MBTL1 (0.59) | L3MBTL1MEN1KMT2APIM1MARK3 | |
| SCHEMBL21246906 | 0.83 | L3MBTL1 (0.59) | L3MBTL1MEN1KMT2APIM1MARK3 | |
| SCHEMBL21259294 | 0.83 | L3MBTL1 (0.59) | L3MBTL1MEN1KMT2APIM1MARK3 | |
| SCHEMBL1196432 | 0.83 | L3MBTL1 (0.62) | L3MBTL1MEN1KMT2APIM1MARK3 | |
| SCHEMBL31370727 | 0.83 | L3MBTL1 (0.45) | L3MBTL1MEN1KMT2APIM1MARK3 | |
| SCHEMBL14222808 | 0.82 | L3MBTL1 (0.57) | L3MBTL1MEN1KMT2APIM1MARK3 | |
| SCHEMBL21259416 | 0.82 | L3MBTL1 (0.57) | L3MBTL1MEN1KMT2APIM1MARK3 | |
| SCHEMBL15853328 | 0.82 | L3MBTL1 (0.57) | L3MBTL1MEN1KMT2APIM1MARK3 | |
| SCHEMBL1055676 | 0.82 | L3MBTL1 (0.57) | L3MBTL1MEN1KMT2APIM1MARK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570632-B2 | Indole derivatives and uses thereof for treating a cancer | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2026-03-10 | — | — | US | disclosed |
| EP-4602047-A1 | THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | The Universite de Montreal (CA) | 2025-08-20 | — | — | EP | disclosed |
| CN-120035595-A | Thiazolo [5,4-d ] pyrimidine compounds, compositions comprising the same and uses thereof | 蒙特利尔大学 | 2025-05-23 | — | — | CN | disclosed |
| WO-2024259241-A1 | 5-HT2A RECEPTOR MODULATORS AND METHODS OF USE THEREOF | Transneural Therapeutics, Inc. (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-4175718-B1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIV CLAUDE BERNARD LYON (FR) | 2024-10-02 | — | — | EP | disclosed |
| CN-115843271-B | Indole derivatives and their use for the treatment of cancer | 克洛德贝纳尔-里昂第一大学 | 2024-08-13 | — | — | CN | disclosed |
| WO-2024077391-A1 | THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | UNIVERSITE DE MONTREAL (CA) | 2024-04-18 | — | — | WO | disclosed |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2023-09-07 | — | — | US | disclosed |
| EP-4175718-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD - LYON 1 (FR) | 2023-05-10 | — | — | EP | disclosed |
| EP-3994133-A1 | HPK1 INHIBITORS AND USES THEREOF | Qilu Regor Therapeutics Inc. (CN) | 2022-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570632-B2 | Indole derivatives and uses thereof for treating a cancer | CKS2, CSNK2A3, CSNK1A1L | L3MBTL1 1953/4885MEN1 3609/4885KMT2A 1423/4885 |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | CSNK2A1, IDO1, CSNK2A3 | L3MBTL1 3699/4885MEN1 2477/4885KMT2A 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.